Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma

通过抑制 HDAC 靶向癌细胞可塑性来逆转 EBV 诱导的鼻咽癌去分化

阅读:9
作者:Jiajun Xie #, Zifeng Wang #, Wenjun Fan #, Youping Liu #, Fang Liu #, Xiangbo Wan #, Meiling Liu, Xuan Wang, Deshun Zeng, Yan Wang, Bin He, Min Yan, Zijian Zhang, Mengjuan Zhang, Zhijie Hou, Chunli Wang, Zhijie Kang, Wenfeng Fang, Li Zhang, Eric W-F Lam, Xiang Guo, Jinsong Yan, Yixin Zeng, Mingyuan

Abstract

Application of differentiation therapy targeting cellular plasticity for the treatment of solid malignancies has been lagging. Nasopharyngeal carcinoma (NPC) is a distinctive cancer with poor differentiation and high prevalence of Epstein-Barr virus (EBV) infection. Here, we show that the expression of EBV latent protein LMP1 induces dedifferentiated and stem-like status with high plasticity through the transcriptional inhibition of CEBPA. Mechanistically, LMP1 upregulates STAT5A and recruits HDAC1/2 to the CEBPA locus to reduce its histone acetylation. HDAC inhibition restored CEBPA expression, reversing cellular dedifferentiation and stem-like status in mouse xenograft models. These findings provide a novel mechanistic epigenetic-based insight into virus-induced cellular plasticity and propose a promising concept of differentiation therapy in solid tumor by using HDAC inhibitors to target cellular plasticity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。